China Meheco(SH:600056) Zhong Guo Chan Ye Jing Ji Xin Xi Wang·2025-07-17 03:01Core Viewpoint - A groundbreaking oral nutritional supplement, "Dr. End PQQ Dihydroquercetin Compound Peptide Effervescent Tablets," developed by the Seiko Telomere Programming Laboratory in collaboration with Harvard Anti-Aging and Anti-Cancer Research Center, is set to launch globally in August 2025, marking a significant advancement in the field of immune modulation and anti-aging cancer prevention [1][7]. Group 1: Product Development and Technology - The product utilizes "Functional Modulation NK Cells" technology to precisely regulate the activity of endogenous NK cells, aiming to restore immune balance and address the decline in NK cell quantity and activity due to aging and environmental factors [3][5]. - The supplement is backed by multiple top-tier invention patents, with international patents in the anti-aging and anti-cancer fields already granted, establishing a strong technological barrier and global leadership [1][5]. Group 2: Clinical Trials and Efficacy - A clinical trial involving 586 participants aged 45-65 demonstrated a significant increase in endogenous NK cell quantity and activity, with an average improvement rate of 21.3% after 24 weeks of continuous use [5]. - The product's safety and reliability are enhanced as it activates the body's endogenous NK cells without external interference, contrasting with the risks associated with exogenous NK cell activation therapies [5][6]. Group 3: Market Launch and Global Impact - The product will be marketed globally by Seiko Pharmaceutical Technology (Jiangsu) Co., Ltd., through the "Dr. End Health Happy Mall," highlighting a milestone in the biopharmaceutical industry and a historic breakthrough in immune modulation and anti-aging cancer prevention [7]. - This launch is expected to inject significant momentum into global health and well-being, ushering in a new era of precise immune protection [7].